Printer Friendly

UPJOHN ENDORSES FDA ADVISORY COMMITTEE RECOMMENDATIONS ON HALCION

 UPJOHN ENDORSES FDA ADVISORY COMMITTEE RECOMMENDATIONS ON HALCION
 WASHINGTON, May 18 /PRNewswire/ -- The Upjohn Company is pleased with the recommendation issued today by the U. S. Food and Drug Administration (FDA) Psychopharmacological Drug Products Advisory Committee. After reviewing Halcion Tablets (triazolam) data, the committee concluded that Halcion is safe and effective when used as recommended.
 Upjohn's Vice Chairman of the Board, Mark Novitch, M.D., said, "The committee's review has confirmed the enormous body of research data worldwide that demonstrates Halcion's safety and effectiveness in the short-term treatment of insomnia. We hope this review will reassure patients who may have been concerned about our product."
 Halcion is the most widely prescribed sleep medication in the world. To date, more than 200 research studies involving more than 10,000 patients, as well as four epidemiological studies involving more than 12,000 patients, have consistently demonstrated Halcion's safety and effectiveness.
 Halcion is registered in more than 80 countries and has been marketed in the United States since 1983.
 The Upjohn Company is a worldwide, research-based provider of human health care products, animal health products, agronomic and vegetable seeds and specialty chemicals.
 Headquartered in Kalamazoo, Mich., the company has been dedicated to improving health and nutrition for more than a century.
 -0- 5/18/92
 /CONTACT: Kaye Bennett of the Upjohn Company, 616-323-4224/ CO: The Upjohn Company ST: Michigan IN: MTC SU: PDT


AH -- NY093 -- 1587 05/18/92 20:16 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 18, 1992
Words:239
Previous Article:CIATTI'S INC. ANNOUNCES RETIREMENT OF WILLIAM C. FERRIL; PHILIP R. DANFORD NAMED INTERIM PRESIDENT AND CHIEF EXECUTIVE OFFICER
Next Article:NORDSTROM RESPONSE TO TODAY'S HEARING IN THE UNION CLASS ACTION LAWSUIT
Topics:


Related Articles
UPJOHN ANNOUNCES NEW U.S. PACKAGING AND LABELING FOR HALCION
UPJOHN APPEALS HALCION SUSPENSION TO U.K. MEDICINES COMMISSION
UPJOHN ELECTS JERRY R. MITCHELL TO BOARD
UPJOHN WELCOMES FDA ADVISORY COMMITTEE MEETING ON HALCION
STRATEGIES FOR THE FUTURE HIGHLIGHT UPJOHN ANNUAL MEETING
UPJOHN REVISES EARNINGS OUTLOOK FOR SECOND QUARTER; ANNOUNCES EARLY RETIREMENT PLAN
ADVISORY COMMISSION RECOMMENDS HALCION RETURN TO U.K. MARKET
FINLAND RETURNS HALCION TO THE MARKET
UPJOHN WINS MASSACHUSETTS HALCION CASE
Advanced Therapeutic Products, Inc. Announces First Product Payments From Nicorette Inhaler and Italian Product Launch

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters